Cystoscopy and Ureteroscopy Market is expected to reach US$ 729.30 Million by 2031

Cystoscope Segment to Lead Cystoscopy and Ureteroscopy Market Based on Product Type During 2025–2031

According to our new research study on “Cystoscopy and Ureteroscopy Market Forecast to 2031 – Global Analysis – by Product Type, Procedure, Technology, Usage Type, And End User,” the cystoscopy and ureteroscopy market size is expected to grow from US$ 459.11 million in 2024 to US$ 729.30 million by 2031; the market is expected to register a CAGR of 6.9% during 2025–2031. Major factors driving the cystoscopy and ureteroscopy market growth include the increasing prevalence of urological diseases and development of technologically advanced and minimally invasive products.

Cystoscopy and ureteroscopy are at the forefront of modern urological care, offering targeted solutions for diagnosing and treating a wide range of urinary tract conditions. These procedures leverage cutting-edge technology through the use of flexible and rigid scopes equipped with high-definition cameras and illumination systems, allowing clinicians to achieve unparalleled visualization of the bladder and urethra. As the field evolves, one of the most transformative cystoscopy and ureteroscopy market trends is the rapid shift toward robotic-assisted surgical techniques, which are redefining precision, efficiency, and patient outcomes in urological interventions.

Cystoscopy and Ureteroscopy Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

Cystoscopy and Ureteroscopy Market Analysis Based on Segmental Evaluation:

Based on product type, the cystoscopy and ureteroscopy market is bifurcated into cystoscope and ureteroscope. In 2024, the cystoscope segment held a significant cystoscopy and ureteroscopy market share. Cystoscopes are essential tools for examining the bladder and urinary tract, and these instruments have undergone significant technological advancements in recent years. Modern cystoscopes feature high-definition imaging, 3D visualization, and fluorescence technologies, which enhance their diagnostic precision. Moreover, innovations such as flexible, miniaturized designs and improved light sources contribute to better access to hard-to-reach areas along with greater patient comfort. Additionally, the integration of artificial intelligence aids in the early detection of abnormalities, further improving diagnostic accuracy.

Several companies are launching new and improved cystoscope models. For example, in September 2022, Photocure ASA announced the global launch of its new and improved Blue Light Cystoscopy (BLC) system, designed to be used with its Hexvix system for detecting bladder cancer. Similarly, in May 2021, the FDA granted clearance to UroViu Corporation to market Uro-G, a flexible, portable, single-use cystoscope. The self-contained Uro-G device features a fully deflectable tip, allowing urologists to use it for diagnostic or interventional procedures in any room in their clinics. Karl Storz and Olympus Corporation offer cutting-edge flexible cystoscopes with superior imaging capabilities. Fujifilm has introduced systems integrated with advanced diagnostic features.  Similarly, Stryker focuses on minimally invasive solutions. Medtronic continues to develop cystoscopes equipped with smart technology, ensuring better patient outcomes. These innovations are shaping the future of urological diagnostics, making procedures more effective and less invasive.

The scope of the cystoscopy and ureteroscopy market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In terms of revenue, North America dominated the cystoscopy and ureteroscopy market share in 2024.

The US dominated the North America cystoscopy and ureteroscopy market in 2024. According to the Department of Urology (University of Florida Health), kidney stones impact 1 in 500 individuals in the US each year. Approximately 1 in 8 men and 1 in 16 women usually develop this condition during their lifetime. The increasing prevalence of kidney stones boosts the demand for cystoscopy and ureteroscopy for early diagnosis and treatment.

According to the National Library of Medicine, UTIs are the most common outpatient infections in the US. The occurrence of UTIs generally increases with age. About 20% of women over 65 experience UTIs, compared to approximately 11% in the overall population. Nearly 50–60% of adult women generally suffer from UTIs at least once in their lifetime.

Recent developments in ureteroscopies and cystoscopies in the US were predominantly made on the technology front to enable more minimally invasive, precise, and patient-centered care. Further, robotic cystoscopes are gaining traction in the medical field, with single-use and robotic-assisted systems offering advancements in cystoscopy procedures. In August 2024, PROCEPT BioRobotics Corporation announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. The HYDROS Robotic System is the only AI-powered platform for Aquablation therapy for benign prostatic hyperplasia (BPH). This proven procedure uses real-time ultrasound and cystoscopy to assist surgeons by providing a detailed view of the prostate, allowing for personalized treatment. With over 400 robotic systems installed, Aquablation therapy has gained remarkable popularity in the US.

The development of flexible ureteroscopes with enhanced imaging capabilities and reduced diameters by prominent industry players—including Karl Storz, Olympus, Stryker, and Richard Wolf—has markedly accelerated growth within the urological device market. These technological advancements offer improved procedural navigation, reduced patient discomfort, and heightened visual clarity during interventions. Olympus obtained regulatory clearance in the United States for its innovative single-use ureteroscope system, RenaFlex, in April 2024. This state-of-the-art solution is designed to provide efficient access to the urinary tract for diagnosing and treating conditions such as kidney stones, utilizing either transurethral or percutaneous techniques.

The rising prevalence of urinary tract disorders, combined with the launch of such advanced medical technologies, continues to fuel the expansion of the cystoscopy and ureteroscopy segment across the US healthcare landscape.

Olympus Corp, Karl Storz SE & Co KG, Richard Wolf GmbH, Ambu A/S, PENTAX Medical, Advin Health Care Pvt Ltd, Coloplast Corp, Cook Medical Holdings LLC, Electronics Services Centre (ESC Medicams), Stryker Corp, Rudra Surgicals, Laborie, Teleflex Inc, NIDHI MEDITECH SYSTEMS, Pioneer Healthcare Technologies, Boston Scientific Corp, Ottomed Endoscopy, Becton Dickinson and Co, SCHÖLLY FIBEROPTIC GMBH, and MicroPort Scientific Corp are among the leading companies profiled in the cystoscopy and ureteroscopy market report.

Based on product type, the cystoscopy and ureteroscopy market is bifurcated into cystoscope and ureteroscope. Based on procedure, the market is segmented into stone management, bladder cancer, benign prostatic hyperplasia (BPH), others. By technology, the market is segmented into fiberoptic and video. In terms of usage type, the market is bifurcated into reusable and single use. By end user, the market is segmented into hospitals, ambulatory surgical centers, and specialty clinics. In terms of geography, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com